Chloe's questions to Syndax Pharmaceuticals (SNDX) leadership • Q2 2025
Question
Chloe, on for George Farmer, asked about real-world cardiac safety monitoring for Revuforge, how to model the Royalty Pharma interest expense, and the market opportunity and positioning for Nyktymbo in idiopathic pulmonary fibrosis (IPF).
Answer
CMO Dr. Nick Botwood assured that QT prolongation is managed well with label guidelines and no new safety concerns have emerged commercially. CFO Keith Goldan explained the royalty expense is 13.8% of Nyktymbo net sales. CEO Michael Metzger described IPF as a large market with high unmet need where Nyktymbo's novel mechanism could be highly impactful, with Phase 2 data expected next year.